NCT06909708

SIRT Versus cTACE for Unresectable HCC (CHANCE2506)

SIRT (Yttrium-90 Carbon Microspheres) Versus cTACE for Unresectable Hepatocellular Carcinoma: A Multicenter, Prospective, Open-label, Phase 3 Trial (CHANCE2506)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 108 (estimated)
• Sponsor: Zhongda Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of yttrium-90 carbon microspheres versus cTACE in patients with unresectable hepatocellular carcinoma

Detailed description

The efficacy and safety of yttrium-90 carbon microspheres versus in patients with unresectable hepatocellular carcinoma (HCC) remain unknown. This multicenter, prospective, open-label, phase 3 trial is designed to evaluate the safety and efficacy of yttrium-90 carbon microspheres versus conventional TACE in patients with hepatocellular carcinoma. The primary endpoint is time to progression for patients with HCC. While the secondary endpoints include the overall response rate, duration of response, local time to progression, tumor biomarkers variation, overall survival and adverse events.

Conditions

• Unresectable Hepatocellular Carcinoma

Interventions

Type	Name	Description
PROCEDURE	SIRT	Y-90 administered
PROCEDURE	cTACE	cTACE administered

Timeline

• Start date: 2025-04-03
• Primary completion: 2026-12-31
• Completion: 2027-01-30
• First posted: 2025-04-03
• Last updated: 2025-04-09

Locations

1 site across 1 country: China